Welcome to LookChem.com Sign In|Join Free

CAS

  • or

614-39-1

Post Buying Request

614-39-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

614-39-1 Usage

Description

Procainamide (hydrochloride) (Item No. 24359) is an analytical reference standard categorized as a local anesthetic. This product is intended for research and forensic applications.

Chemical Properties

White to slightly yellow powder

Uses

Different sources of media describe the Uses of 614-39-1 differently. You can refer to the following data:
1. Class I antiarrhythmic
2. These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
3. Procainamide hydrochloride (PAH) is suitable to investigate its binding behavior with human serum albumin and bovine serum albumin by fluorescence quenching study to understand the pharmacokinetic and pharmacodynamic mechanisms of PAH.

Definition

ChEBI: A hydrochloride which has procainamide as the amino component.

General Description

Procainamide hydrochloride,p-amino-N-[2-(diethylamino)ethyl]benzamidemonohydrochloride, procainamidium chloride (Pronestyl,Procan SR), has emerged as a major antiarrhythmic drug. Itwas developed in the course of research for compoundsstructurally similar to procaine, which had limited effectas an antiarrhythmic agent because of its central nervoussystem (CNS) side effects and short-lived action causedby rapid hydrolysis of its ester linkage by plasma esterases.Because of its amide structure, procainamide hydrochlorideis also more stable in water than is procaine. Aqueoussolutions of procainamide hydrochloride have a pH ofabout 5.5. A kinetic study of the acid-catalyzed hydrolysisof procainamide hydrochloride showed it to be unusuallystable to hydrolysis in the pH range 2 to 7, even at elevatedtemperatures.

Biochem/physiol Actions

Procainamide hydrochloride is a sodium channel blocker and Class IA anti-arrhythmic. It has also been shown to Inhibit DNA methyltransferase and modulate epigenetic regulation of gene expression.

Clinical Use

Procainamide hydrochloride is metabolized through theaction of N-acetyltransferase. The product of enzymaticmetabolism of procainamide hydrochloride is N-acetylprocainamide(NAPA), which possesses only 25% of the activityof the parent compound.26 A study of the disposition ofprocainamide hydrochloride showed that 50% of the drugwas excreted unchanged in the urine, with 7% to 24% recoveredas NAPA.28,29 Unlike quinidine, procainamide hydrochlorideis bound only minimally to plasma proteins.Between 75% and 95% of the drug is absorbed from the gastrointestinaltract. Plasma levels appear 20 to 30 minutesafter administration and peak in about 1 hour.30Procainamide hydrochloride appears to have all of theelectrophysiological effects of quinidine. It diminishesautomaticity, decreases conduction velocity, and increasesaction potential duration and, thereby, the refractory periodof myocardial tissue. Clinicians have favored the use of procainamidehydrochloride for ventricular tachycardias andquinidine for atrial arrhythmias, even though the two drugsare effective in either type of disorder.

Veterinary Drugs and Treatments

Procainamide potentially may be useful for the treatment of ventricular premature complexes (VPC’s), ventricular tachycardia, or supraventricular tachycardia associated with Wolff-Parkinson- White (WPW) syndrome with wide QRS complexes. Higher doses may be beneficial in the treatment of supraventricular tachycardias, although procainamide cannot be considered a first-line agent for this dysrhythmia.

Check Digit Verification of cas no

The CAS Registry Mumber 614-39-1 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 6,1 and 4 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 614-39:
(5*6)+(4*1)+(3*4)+(2*3)+(1*9)=61
61 % 10 = 1
So 614-39-1 is a valid CAS Registry Number.
InChI:InChI=1/C13H21N3O.2ClH/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11;;/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17);2*1H

614-39-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma-Aldrich

  • (P3050000)  Procainamide hydrochloride  European Pharmacopoeia (EP) Reference Standard

  • 614-39-1

  • P3050000

  • 1,880.19CNY

  • Detail
  • Sigma

  • (P9391)  Procainamide hydrochloride  

  • 614-39-1

  • P9391-25G

  • 389.61CNY

  • Detail
  • Sigma

  • (P9391)  Procainamide hydrochloride  

  • 614-39-1

  • P9391-100G

  • 1,313.91CNY

  • Detail
  • USP

  • (1563502)  Procainamide hydrochloride  United States Pharmacopeia (USP) Reference Standard

  • 614-39-1

  • 1563502-200MG

  • 4,662.45CNY

  • Detail

614-39-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name procainamide hydrochloride

1.2 Other means of identification

Product number -
Other names Procainamide hydrochloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:614-39-1 SDS

614-39-1Upstream product

614-39-1Relevant articles and documents

Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders

-

, (2008/06/13)

The present invention provides compositions and methods for the treatment of pain, inflammation or inflammation-mediated disorders in a subject. More particularly, the invention provides a combination therapy for the treatment of pain, inflammation or inflammation mediated disorders comprising the administration to a subject of a sodium ion channel blocker in combination with a cyclooxygenase-2 selective inhibitor.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 614-39-1